A Post-Marketing Observational Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatment of Advanced Prostate Cancer
18 Years
N/A
Male
Prostatic Neoplasm
Trial Information
A Post-Marketing Observational Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatment of Advanced Prostate Cancer
Inclusion Criteria:
- Patients with advanced prostate cancer who have been prescribed Lucrin/
Lucrin-Tri-depot or any other treatment with local reimbursement guidelines; Patients
willing to consent to data being collected and provided to Abbott Laboratories.
Exclusion Criteria:
- Contraindications according to the Summary of Product Characteristics (SPC).
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit
Outcome Description:
The number of participants with metastases that are absent, local tumor, single metastases, multiple metastases in 1 organ, and multiple metastases in multiple organs at each visit is summarized.
Outcome Time Frame:
time 0 (Baseline), month 3, and every 3 months until disease progression or up to 24 months, whichever came first
Safety Issue:
No
Principal Investigator
Simonne Lens
Investigator Role:
Study Director
Investigator Affiliation:
Abbott
Authority:
Belgium: Institutional Review Board
Study ID:
PMOS-BELG-04-001
NCT ID:
NCT01081873
Start Date:
June 2004
Completion Date:
December 2010
Related Keywords:
- Prostatic Neoplasm
- Multicenter study
- Neoplasms
- Prostatic Neoplasms
Name | Location |
|---|
